Noevir saw the highest growth of 24% in patent filings and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 24% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Noevir’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Noevir has been focused on protecting inventions in Japan(JP) with four publications in Q4 2023
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The Japan(JP) patent Office are among the top ten patent offices where Noevir is filings its patents. Among the top granted patent authorities, Noevir has 100% of its grants in Japan(JP)
Patents related to rare diseases lead Noevir's portfolio
Noevir has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q4 2023.
Cosmetics & toiletries related patents lead Noevir portfolio followed by skincare, and haircare
Noevir has highest number of patents in cosmetics & toiletries followed by skincare, haircare, anti-agers.
For comprehensive analysis of Noevir's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.